Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Abstract Text:

    daniel b costaDaniel B Costa, halmos Halmos,amit kumarAmit Kumar,susan t schumerSusan T Schumer,mark s hubermanMark S Huberman,titus j boggonTitus J Boggon,daniel g tenenDaniel G Tenen,susumu kobayashiSusumu Kobayashi,daniel b costaDaniel B Costa, halmos Halmos,amit kumarAmit Kumar,susan t schumerSusan T Schumer,mark s hubermanMark S Huberman,titus j boggonTitus J Boggon,daniel g tenenDaniel G Tenen,susumu kobayashiSusumu Kobayashi,daniel b costaDaniel B Costa, halmos Halmos,amit kumarAmit Kumar,susan t schumerSusan T Schumer,mark s hubermanMark S Huberman,titus j boggonTitus J Boggon,daniel g tenenDaniel G Tenen,susumu kobayashiSusumu Kobayashi,

    BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. These EGFR-dependent tumors eventually become TKI resistant, and the common secondary T790M mutation accounts for half the tumors with acquired resistance to gefitinib. However, the key proapoptotic proteins involved in TKI-induced cell death and other secondary mutations involved in resistance remain unclear. The objective of this study was to identify the mechanism of EGFR TKI-induced apoptosis and secondary resistant mutations that affect this process. METHODS AND FINDINGS: To study TKI-induced cell death and mechanisms of resistance, we used lung cancer cell lines (with or without EGFR mutations), Ba/F3 cells stably transfected with EGFR mutation constructs, and tumor samples from a gefitinib-resistant patient. Here we show that up-regulation of the BH3-only polypeptide BIM (also known as BCL2-like 11) correlated with gefitinib-induced apoptosis in gefitinib-sensitive EGFR-mutant lung cancer cells. The T790M mutation blocked gefitinib-induced up-regulation of BIM and apoptosis. This blockade was overcome by the irreversible TKI CL-387,785. Knockdown of BIM by small interfering RNA was able to attenuate apoptosis induced by EGFR TKIs. Furthermore, from a gefitinib-resistant patient carrying the activating L858R mutation, we identified a novel secondary resistant mutation, L747S in cis to the activating mutation, which attenuated the up-regulation of BIM and reduced apoptosis. CONCLUSIONS: Our results provide evidence that BIM is involved in TKI-induced apoptosis in sensitive EGFR-mutant cells and that both attenuation of the up-regulation of BIM and resistance to gefitinib-induced apoptosis are seen in models that contain the common EGFR T790M and the novel L747S secondary resistance mutations. These findings also suggest that induction of BIM may have a role in the treatment of TKI-resistant tumors.

    BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Publishing Authors By Initials

    db costaDB Costa,b halmosB Halmos,a kumarA Kumar,st schumerST Schumer,ms hubermanMS Huberman,tj boggonTJ Boggon,dg tenenDG Tenen,s kobayashiS Kobayashi,db costaDB Costa,b halmosB Halmos,a kumarA Kumar,st schumerST Schumer,ms hubermanMS Huberman,tj boggonTJ Boggon,dg tenenDG Tenen,s kobayashiS Kobayashi,db costaDB Costa,b halmosB Halmos,a kumarA Kumar,st schumerST Schumer,ms hubermanMS Huberman,tj boggonTJ Boggon,dg tenenDG Tenen,s kobayashiS Kobayashi,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: PLoS medicine

    VOLUME: 4

    Page Numbers: 1669-79; discussion 1680

    Journal Abbreviation: PLoS Med.

    ISSN: 1549-1676

    DAY: 30

    MONTH: Oct

    YEAR: 2007

    BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 101231360

    BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

    AFFILIATION: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NCI

    GRANT: K99CA126026

    ACRONYM: CA

    MEDLINETA: PLoS Med

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News